1. Introduction {#sec1}
===============

Neurocognitive disorders (NCDs), defined in accordance with the Diagnostic and Statistical Manual, Edition 5: DSM-5 criteria, are an umbrella term for cognitive disorders formerly known as dementia \[[@bib1],[@bib2]\]. Some examples include major NCDs due to Alzheimer\'s disease (AD), vascular disease, or Parkinson\'s disease. Mild neurocognitive impairment, also termed mild cognitive impairment, can be a prodromal state of major NCD. Both incidence and prevalence increase with age \[[@bib3]\], with substantial costs representing a challenge for the economy \[[@bib4]\]. For individuals with NCDs, changes in cognition, behavior, and emotions can lead to progressive and irreversible functional limitations, affecting everyday activities and autonomy \[[@bib5]\].

Virtual reality (VR) is an emerging technology that digitally provides a three-dimensional environment, allowing persons to interact, provide sensory inputs, and track changes \[[@bib6]\]. VR can be presented in fully immersive (high level of immersion) or nonimmersive environments (low level of immersion) \[[@bib7],[@bib8]\]. Immersion provides a sense of presence in the virtual world with an immersive display device (e.g. head-mounted display) and an interactive device (e.g. joystick, glove). VR has been used in health care and education for both rehabilitation and training purposes \[[@bib9], [@bib10], [@bib11], [@bib12]\]. VR technologies are an innovative rehabilitation approach to minimize the negative impact of NCDs on individuals, families, and society.

VR has been successfully used in the elderly and in individuals who had stroke and Parkinson\'s disease to enhance the ability to perform activities of daily living \[[@bib13]\], in individuals at high risk for cognitive decline \[[@bib14]\] to reduce anxiety in older adults consulting for the first time in a memory clinic \[[@bib15]\], and in individuals with NCDs for memory rehabilitation \[[@bib16]\]. Interestingly, VR has been used in the diagnosis, cognitive training, and caregiver education for major NCD due to AD \[[@bib17],[@bib18]\], to improve executive function in individuals with NCDs due to traumatic brain injury \[[@bib19]\], cognitive rehabilitation of mild cognitive impairment \[[@bib20], [@bib21], [@bib22]\], and stroke \[[@bib23],[@bib24]\]. The evidence is sparse, and a comprehensive picture of the effects of VR interventions on NCDs is needed. That is, an overall description of the use of VR in the cognitive rehabilitation of NCDs remains predominantly undetermined. We aim to systematically review VR studies focused on cognitive rehabilitation in NCDs. As a secondary objective, we aimed to identify changes in psychological functioning (e.g. improved well-being and reduction of emotional problems) after VR interventions in NCDs.

2. Methods {#sec2}
==========

2.1. Search strategy and information sources {#sec2.1}
--------------------------------------------

A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) systematic review was conducted using the keywords ("Dementia" OR "Cognitive impairment") and ("Virtual reality" OR "Virtual-based") with different combinations of those terms in the databases MEDLINE/PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, LILACS, SciELO, PEDro, CINAHL, and Scopus from inception to November 2018. A librarian and a clinical neuropsychologist helped the team to refine the search strategy and the search was cross-validated by a second librarian. A reference manager software was used -- EndNote X9 \[[@bib25]\].

The systematic review has been registered in PROSPERO: (registration number: CRD42019121953).

2.2. Study selection {#sec2.2}
--------------------

Eligibility of the studies followed inclusion criteria: (1) VR interventions conducted in adults with NCDs of different etiologies (e.g. AD, vascular disease, Parkinson\'s disease, and mild cognitive impairment); (2) Studies conducted in the community, hospital, or residential care; (3) Studies measuring cognition before and after VR interventions. Interventions included the use of any type of immersive and nonimmersive VR technology targeting cognition in individuals with NCDs; (4) Quantitative, qualitative, and mixed studies; (5) Feasibility studies (i.e., user acceptance and adverse effects); and (6) Studies available in the English language. We excluded studies based on the following characteristics: (1) Studies conducted in individuals with traumatic brain injury and delirium; (2) Studies focusing on family or professional caregivers of individuals with NCD or outcome measures that focused on family members and professional caregivers of individuals living with NCD; (3) Research protocols and reviews; (4) Expert letters, opinion pieces, notes, editorials, and book chapters; and (5) Conference papers and abstracts.

2.3. Data extraction and synthesis {#sec2.3}
----------------------------------

First, titles and abstracts were screened by two independent reviewers (i.e., a researcher in VR and a clinical neuropsychologist) based on the eligibility criteria. Studies meeting the inclusion criteria, or studies that were unclear, were retained for full-text review. Discrepancies were resolved by consensus and a third reviewer for determination. Second, two reviewers independently extracted the following information from each study: Publication data (i.e., author, year, and title), study design, objectives, setting, participants (e.g. sample size, mean age, sex, ethnicity, diagnosis, NCD severity, NCD duration, and the demographic information for control groups when available), VR intervention (i.e., name of the VR application, technical information, subjective and objective level of immersion based on published guidelines \[[@bib7]\], the number of VR sessions and frequency, length of each VR session, and VR overall mean duration), outcome measures, results, user acceptance, adverse effects, generalization, and the general conclusion.

2.4. Levels of VR immersion {#sec2.4}
---------------------------

The level of immersive capability of VR technologies was assessed using five criteria \[[@bib7],[@bib8]\]: (1) Inclusiveness that refers to whether a VR technology eliminates signals indicating the existence of a physical world separate from the virtual world (e.g. joystick, weight of wearable devices, and external noise); (2) Extensiveness refers to the number of sensory modalities accommodated; (3) Surrounding involves the visual presentation of the VR technology, to which the physical world is shut out (e.g. head-mounted display, surround projection, and computer screen); (4) Vividness corresponds to the fidelity and resolution with which the VR technology simulates the desired environment (e.g. visual information and functionality); and (5) Matching to whether the viewpoint of the VR technology is modified to match the user\'s perspective through motion capture.

Each one of the five criteria influences, but may not be the sole determinant of, the user\'s perceptual experience \[[@bib7],[@bib8]\]. In this systematic review, we objectively classified VR technologies as low, moderate, or highly immersive based on the extent to which they met \[[@bib7]\] criteria. When a study differed in the level of immersion across multiple aspects, we averaged across criteria to determine a global immersion rating. For example, if a VR technology met low criteria on one aspect, moderate criteria on three aspects, and high criteria on one aspect, it was classified as moderate immersion. The numerical score was calculated by converting the scores of each aspect into a numerical value (low = 1, moderate = 2, and high = 3) to estimate an overall mean score for each VR technology.

2.5. Risk of bias and quality assessment {#sec2.5}
----------------------------------------

Two reviewers independently appraised the included studies using the Downs and Black tool (1998). The tool contains 27 questions across five sections and provides both an overall score for study quality and a bias score. The five sections included (1) study quality -- 10 items, (2) external validity -- 3 items, (3) study bias -- 7 items, (4) confounding and selection bias -- 6 items, and (4) power of the study -- 1 item. Items are scored from 0 ("no") to 1 ("yes"), excepting item 5 (scores ranging from 0--2; 0 = no; 1 = partially, and 2 = yes) and item 27 (scores ranging from 0--5; 0 = No power calculation is provided; 3 = The power calculation is provided but the importance or impact of the difference between groups used in the calculation is unclear; 5 = The difference between groups is clearly defined as a clinically important difference.) Downs and Black total score ranges were given in corresponding quality levels: (1) excellent (≥26), (2) good (20--25), (3) fair (15--19), and (4) poor (≤14) \[[@bib26]\]. Only randomized studies could achieve a quality level of excellent in accordance with the scoring methodology of the Downs and Black checklist.

2.6. Strategy for data synthesis {#sec2.6}
--------------------------------

A critical analysis of the literature was performed based on (1) a descriptive numerical summary based on the characteristics of the studies, samples, diagnoses, and types of VR technologies; (2) level of immersion; and (3) risk of bias and quality assessment of the studies. Based on the information available, the suitability of a meta-analysis was considered.

3. Results {#sec3}
==========

Of 404 studies, a total of 22 were included in the systematic review, for an aggregated sample of 564 individuals with NCDs participating in these studies ([Fig. 1](#fig1){ref-type="fig"}). Given the variability in study outcomes, it was not feasible to conduct a meta-analysis. Most of the included studies were conducted in individuals with NCDs due to stroke (27.3%) \[[@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32]\], followed by mild cognitive impairment (22.7%) \[[@bib33], [@bib34], [@bib35], [@bib36], [@bib37]\], and AD (13.6%) \[[@bib38], [@bib39], [@bib40]\]. In addition, 13.6% of the 22 studies included samples with nonspecified NCD \[[@bib38], [@bib39], [@bib40]\], and 22.7% included groups with suspected NCD (e.g. questionable dementia and presence of memory deficits), multiple sclerosis, or diagnosis not confirmed \[[@bib41], [@bib42], [@bib43], [@bib44], [@bib45]\].Fig. 1PRISMA flow diagram for virtual reality and neurocognitive disorders. Abbreviation: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

3.1. Clinical information {#sec3.1}
-------------------------

Information of each study including the objective, clinical characteristics of the sample, main outcomes, and results is presented in [Table 1](#tbl1){ref-type="table"}. The Mini-Mental State Examination \[[@bib49]\] was the most widely used tool to determine the severity of the NCDs with a wide range in the scores (10--30), followed by the Montreal Cognitive Assessment \[[@bib50]\] with scores ranging from 18 to 30 points. Outcome measures include traditional neuropsychological tests (e.g. Rey Auditory Verbal Learning Test and Trail Making Test), as well as measures of suitability and acceptability. In general, the results of the interventions indicate an improvement at different levels of cognition (e.g. memory, dual tasking, and visual attention). Secondarily, a reduction in psychological aspects was confirmed after VR interventions targeting cognition (e.g. reduction of anxiety, higher levels of well-being, and increased use of coping strategies). Only one study showed no change in cognitive outcomes after the VR intervention most likely related to the relatively short training period and lack of training specificity for improving cognitive performance \[[@bib37]\]. The rest showed positive outcomes or the feasibility to deliver the intervention. However, most of the studies did not report effect sizes (see [Table 1](#tbl1){ref-type="table"}).Table 1Clinical information, outcomes, and main conclusions of studies on VR and NCDsAuthorObjectiveSample sizeDiagnosisNCD severityOutcome measuresEffect sizesConclusionBlackman et al. \[[@bib46]\]To evaluate the validity and reliability of a computer-generated virtual environment.38Mild to moderate dementia (AD and vascular)MMSE = 15--29Navigability, legibility, safety, comfort, and well-beingReported only for task performance (r = nonsignificant to −0.53) between real and virtual.As impairment increases, the environment becomes more challenging for participants.Davis et al. \[[@bib38]\]To examine the effect of salient visual cues on the wayfinding performance of older adults with and without AD.88 (50 in the control condition, 38 with NCD)MCI and ADMMSE and MoCA: 25.87 (3.01) and 18.97 (3.58) for AD and MCI and 29.16 (0.99) and 25.64 (2.09) for healthy controls, respectivelySpeed of navigation (time needed to find the destination as a measure of learning) and the number of goal acquisitions[∗](#tbl1fnlowast){ref-type="table-fn"} Cohen\'s d of 0.52 for goal acquisitions in the AD/MCI groupSalient cues increase navigation speed and goal acquisition in individuals with AD/MCI.De Luca et al. \[[@bib27]\]To determine the effects of a VR intervention on cognitive function in patients who had stroke, as compared with traditional cognitive rehabilitation.12Ischemic or hemorrhagic stroke in the chronic stageMMSE = 10--23MoCA, frontal assessment battery, attentive matrices, and trial making testNot reported and data insufficient to calculate itBTs-Nirvana was successful at improving function in cognitive domains for patients who had stroke, relative to a control group.De Luca et al. \[[@bib28]\]To evaluate the effects of combined conventional and VR rehabilitation techniques on cognitive functioning in an individual who had stroke.1Hemorrhagic stroke in the postacute phaseNot specifiedCognition, attention, anxiety, depression, coping strategies, and functional statusNot reported this as a case study.Relaxation and respiratory techniques in a semi-immersive VR environment are superior to conventional relaxation and respiratory techniques in improving attention, coping strategies, and in reducing anxiety symptoms.Delbroek et al. \[[@bib33]\]To investigate whether VR training improves cognitive, balance, and dual-task performance in older adults with MCI.20MCIMoCA \< 26MoCA, the Dutch version of the Intrinsic Motivation Inventory (IMI), and the Observed Emotion Rating Scale (OERS)[∗](#tbl1fnlowast){ref-type="table-fn"} Cohen\'s d of 0.16 for MoCAThe VR technology was successful at improving balance and dual-tasking in older adults with MCI with no changes in global cognition.Faria, et al. \[[@bib29]\]To observe the effect of VR rehabilitation on the functioning of individuals who had stroke.18StrokeMMSE ≥ 15Addenbrooke Cognitive Examination (primary outcomes) and the Trail Making Test A and B, Picture Arrangement from WAIS-III and Stroke Impact Scale 3.0 (secondary outcomes)r\'s ranging from 0.01 to 0.85Cognitive rehabilitation through an ecologically valid VR system has more impact than conventional methods.Flynn et al. \[[@bib47]\]To examine the feasibility of VR technology for use by persons with dementia.6DementiaOnly one score known for one participant: MMSE = 12Psychological well-beingNot reported and data insufficient to calculate it.People with dementia have little difficulty in navigating VR environments and face no changes in psychological and physical well-being as a result of exposure to the VE.Hwang & Lee \[[@bib34]\]To investigate the effect of VR on cognitive function and balance in elderly individuals with MCI.24 (12 in experimental, 12 in control)MCIMMSE experimental = 22.4 ± 0.7. MMSE controls = 22.3 ± 0.7Memory (Visual Span Test) and attention (WCT)[∗](#tbl1fnlowast){ref-type="table-fn"} Cohen\'s d between 0.14 and 0.5 in the experimental groupThe VR program is one of the effective intervention methods for improving cognitive functions such as memory.Kim et al. \[[@bib30]\]To investigate the effect of VR on cognitive recovery in individuals who had stroke.28 (15 in experimental, 13 in control)StrokeMMSE experimental = 17.5 ± 3.9. MMSE controls = 16.4 ± 6.3Computerized neuropsychological test (CNT, MaxMedica) and the Tower of London test[∗](#tbl1fnlowast){ref-type="table-fn"} Cohen\'s d between 0.48 and 0.84 in the experimental groupVisual attention and short-term visuospatial memory showed significant improvement in the VR group compared with the control group.Kizony et al. \[[@bib41]\]To document the service delivery implemented by the VR system for people with ABI, over 2 years.82 (74 with ABI, 8 with MS)ABI or MSMMSE ABI (n = 30) = 27.6 ± 1.9 (23--30); MoCA ABI (n = 39) = 25.8 ± 3.1 (18--30); MMSE MS (n = 2) = 29.0 ± 1.4 (28--30); MoCA MS (n = 6) = 28.5 ± 1.9 (25--30)Trail Making Test A and BNot reported and data insufficient to calculate it.The significant improvements in the participants\' scores on the TMT (entailing visuomotor scanning, divided attention, and cognitive flexibility) point to its effectiveness for a population that does not typically receive intensive therapy.Lee et al. \[[@bib31]\]To explore patient-perceived difficulty and enjoyment during VR-based rehabilitation and the factors affecting those experiences.8StrokeMMSE = 10--29Levels of difficulty, enjoyment, and training intensity were assessed quantitatively with a visual analog scale.Only provided for physical outcomes (Cohen\'s d between 0.50 and 0.96).There was an enjoyment of the VR program when task difficulty and patient abilities were matched.Man et al. \[[@bib42]\]To develop and implement VR-based memory training for older adults with dementia, and to examine the efficacy of the intervention on cognitive functions.44 (20 in VR group, 24 in the therapist-led group)Questionable dementiaVR group mean MMSE = 21.05, therapist-led group mean MMSE = 23Multifactorial Memory Questionnaire and Fuld Object-Memory Evaluation[∗](#tbl1fnlowast){ref-type="table-fn"} Cohen\'s d between 0.03 and 2.2 in the experimental groupNonimmersive VR participants showed greater improvements in objective memory performance as compared with a non-VR group, suggesting that VR may be a useful tool in memory rehabilitation.Manera et al. \[[@bib48]\]To assess the acceptability, interest, and usability of VR in individuals with MCI.57 (28 with MCI and 29 with dementia)MCI or dementiaMMSE MCI = 25.4 ± 2.6. MMSE Dementia: 20.2 ± 3.1Level of satisfaction, interest, discomfort, anxiety, the feeling of security, and fatigueNot reported and data insufficient to calculate it.Both participants with MCI and dementia were highly satisfied and interested in the attentional task, and reported high feelings of security and low discomfort, anxiety and fatigue.Mirza & Yaqoob \[[@bib35]\]To observe the effects of VR cognitive training on cognition, blood pressure, and glucose levels in an individual with MCI.1MCIMMSE = 23; MoCA = 24General cognition, verbal fluency, and TMT scoresNot reported this as a case study.VR successfully improved cognitive functioning in one individual with MCI.Moyle et al. \[[@bib39]\]To measure and describe the effectiveness of a VR program on engagement, apathy, and mood states of people with dementia.29 (10 individuals with dementia, 10 family members, and 10 staff members)Dementia (Alzheimer = 7, Undisclosed = 3)Psychogeriatric Assessment Scale = 13.21Observed Emotion Rating Scale, Person--Environment Apathy Rating, and type of engagement[∗](#tbl1fnlowast){ref-type="table-fn"} Cohen\'s d between 0.08 and 1.5 in the group of individuals with dementiaParticipants experienced more pleasure and a greater level of alertness.Mrakic-Sposta et al. \[[@bib36]\]To evaluate the impact of an innovative-combined physical activity and cognitive training based on VR in individuals with MCI.10MCIMMSE: 23.0 ± 3.4Cognition (extensive neuropsychological battery: Attentional Matrices Test; RAVLT; ROCFT; TMT-A; Frontal Assessment Battery) and acceptability[∗](#tbl1fnlowast){ref-type="table-fn"} Cohen\'s d between 0.46 and 2.21 in the experimental groupThe combined VR training protocol was able to effect MMSE tasks and to increase the global cognition levels of MCI.Optale et al. \[[@bib43]\]To test the efficacy of a program of VR memory training in a group of rest-home residents with objective memory deficits.36 (15 experimental, 16 control)Presence of memory deficitsMemory deficits as documented by a corrected total score at the Verbal Story Recall Test below the cutoff value (15.76). MMSE experimental = 22.9 ± 5. MMSE controls = 20.99 ± 4.75General cognitive abilities, verbal memory, executive functions, and visuospatial processing, and depressionCohen\'s d between −0.33 and 0.75 for the training session and between −0.32 and 0.4 for the booster session.The particular nature of the VR training may allow memory function training even with those affected by severe memory impairment.Park & Yim \[[@bib44]\]To investigate whether a VR program could improve cognitive functioning and muscle strength and balance in community-dwelling elderly.72 (36 experimental, 36 control)UndiagnosedMMSE experimental = 22.63 ± 4.91. MMSE controls = 22.88 ± 4.18MoCA[∗](#tbl1fnlowast){ref-type="table-fn"}Cohen\'s d of 0.43 in the experimental groupPhysical activity via VR program decreased risked cognitive impairment.Schwenk et al. \[[@bib37]\]To evaluate the feasibility and experience in using VR training in individuals with amnestic MCI.22 (12 experimental, 10 control)Amnestic MCIMoCA score averaged 23.3 ± 2.6, experimental = 23.3 ± 3.1, control = 22.4 ± 3.0MoCA and the Trail Making A and B testsOnly provided for physical outcomes (Balance indicators -- Partial eta squared ranging from 0.213 to 0.257).Lack of effect on cognitive performance most likely related to the relatively short training period and lack of training specificity for improving cognitive performance.Threapleton et al. \[[@bib32]\]To explore the feasibility of using a VR intervention to support discharge after a stroke.16 (intervention = 8, control = 8)StrokeNIHSS scale: minor stroke (1--4) 5 (31.25%); moderate stroke (5--15) 9 (56.25%); moderate to severe stroke (16--20) 1 (6.25%); severe stroke (21--42) 0 (0%); missing 1 (6.25%)Health-related quality of life and a measure of satisfaction was obtained using the Patient Satisfaction Index.[∗](#tbl1fnlowast){ref-type="table-fn"} Cohen\'s d between 0.02 and 1.22 in the experimental groupIt was feasible to recruit, randomize, and retain participants for follow-up assessments and to deliver the intervention to support discharge after stroke.Vallejo et al. \[[@bib45]\]To determine which VR interface is more acceptable to an elderly population for rehabilitation purposes.20Undiagnosed (Dementia?)Not reportedSystem Usability ScaleNot reported and data insufficient to calculate it.To create a serious game based rehabilitation program, it is essential to take into account the usability of the involved devices, the person\'s abilities and also the motivations to play of the target population.White & Moussavi \[[@bib40]\]To observe whether a VR navigation task can be used for neurocognitive treatment in an individual with Alzheimer\'s disease.1MCI vs. possible ADMoCA = 24MMSE and MoCANot reported this as a case study.The VR treatment has shown some benefits for one person at an early stage of AD.[^1][^2]

3.2. VR technology and reported levels of immersion {#sec3.2}
---------------------------------------------------

[Table 2](#tbl2){ref-type="table"} shows different VR levels of immersion as reported in the studies, the characteristics of the VR programs, and user experience. In regard to the description of the levels of immersion, as provided in the studies, 50% of the technologies were described as semi-immersive, 18.2% as immersive, 18.2% as nonimmersive, and 13.6% did not describe the level of immersion. The average number of sessions delivered for the 22 studies was 13.8 (SD = 14, range = 1--60). The average duration of a single session across the 22 studies was 31.4 minutes (SD = 11.3, range = 5--50). A total of 40.9% of the studies did not report any data regarding user acceptance. On average, the remaining studies indicated a good level of acceptance associated with enjoyment with the technology, user satisfaction, interest, engagement, motivation, safety, helpfulness, and easiness of use. Interestingly, adverse effects were not reported in 59.1% of the studies. Among the adverse effects reported, the most frequent ones included simulator sickness \[[@bib38]\], negative emotions when participants fail in specific activities facilitated by the technology \[[@bib33]\], oculomotor disturbances, nausea, and disorientation \[[@bib47]\], neck pain \[[@bib31]\], and some dizziness \[[@bib44]\]. Only one study clearly indicated an absence of training-related adverse events \[[@bib37]\]. The remaining studies indicated no adverse effects.Table 2VR levels of immersion, characteristics of the VR programs, and user experienceTitleName of VR applicationSubjective level of immersionNumber of VR sessions and frequencyLength of each VR sessionUser acceptanceAdverse effectsBlackman et al. \[[@bib46]\]Not specifiedSemi-immersiveTwo sessions: (A) real-world and simulated VE walk and (B) adapted VE walkNot specifiedPartial because of technical difficulties (e.g. detailed resolution and reproduction of real-world peripheral vision and challenges to use the joystick).Not reportedDavis et al. \[[@bib38]\]Virtual Senior LivingSemi-immersiveEach participant experienced 10 trials in each condition: 20 trials over two days.30 minutes with a 15-minute breakNot specified16 participants (control group n = 10, 19%; AD/MCI group n = 6, 12%) withdrew because of simulation sickness.De Luca et al. \[[@bib27]\]BTs NirvanaSemi-immersiveThree sessions weekly for two months40 minutesNot specifiedNot reportedDe Luca et al. \[[@bib28]\]BTs NirvanaSemi-immersive24 sessions, three times a week for 8 weeks45 minutesNot specifiedNot reportedDelbroek et al. \[[@bib33]\]BioRescueSemi-immersive2 sessions a week for 6 weeksIncreasing length: 18 minutes in week one to 30 minutes in week 5Participants found the VR training to be pleasant and useful for concentration, memory, and balance.Overall, sadness, anger, and anxiety appeared only as a small reaction to the failure of an exercise.Faria, et al. \[[@bib29]\]Reh\@CityNot specified12 sessions throughout 4 to 6 weeks20 minutes per sessionGood usability and satisfaction with the system with no reported problems using the interface.Not reportedFlynn et al. \[[@bib47]\]VE BG with Systems Flybox joystickSemi-immersiveTwo sessions50 minutes total, including 20 minutes per VR experience (2), and a 10--15 minute breakParticipants perceived some objects as being realistic and moved naturally, felt in control of the simulation, and demonstrated the ease in using the joystick.Oculomotor disturbances \> nausea \> disorientationHwang & Lee \[[@bib34]\]BioRescueNot specified20 sessions over 4 weeks30 minutesNot specifiedNot reportedKim et al. \[[@bib30]\]IREXNot specified3 times a week for 4 weeks30 minutesParticipants found the system to be highly useable for rehabilitation and reported a high level of enjoyment.Not reportedKizony et al. \[[@bib41]\]CogniMotionSemi-immersiveTwice a week for 2 months30 minutesParticipants reported high levels of system usability and enjoyment.Not reportedLee et al. \[[@bib31]\]VR programSemi-immersive5--8 sessions, 3 days per week20--30 minutesSome participants with normal cognitive ability could not understand the rules, whereas participants with MCI could enjoy the game with only minimal assistance.One participant said that she became reluctant to do the training because of pain in the back of her neck and flank while performing the training.Man et al. \[[@bib42]\]VR programNonimmersive10 sessions, over 2--3 times a week30 minutesNot specifiedNot reportManera et al. \[[@bib48]\]VR programNonimmersiveSingle session5 minutesParticipants reported a preference for the VR condition as compared with the paper condition. Low levels of anxiety, fatigue, and discomfort, and high levels of satisfaction, interest, and feelings of security with the VR program.Difficulties in using the mouse to select the targets, and possibly due to eye strain from wearing the 3D glasses, and to the global VR setup, which was new to most of the participants.Mirza & Yaqoob \[[@bib35]\]A combined aerobic-VR cognitive training programNot specified3 days a week for 12 weeks30 minutesNot specifiedNot reportedMoyle et al. \[[@bib39]\]VR ForestImmersiveSingle session15 minutes maximum, Mean = 10.22 (SD = 1.07)The majority of participants reported a positive perception. The staff reported very few technical difficulties with setting up the technology.50% of participants expressed significantly greater levels of anxiety/fear during the experience.Mrakic-Sposta et al. \[[@bib36]\]VR programSemi-immersive3 sessions per week for 6 weeks40--45 minutesParticipants enjoyed the VR program, with high levels of engagement and motivation.Some reports of a slight sense of sickness.Optale et al. \[[@bib43]\]VR memory training (VRMT)Immersive3 sessions per week for 3 months in the initial phase, 2 sessions a week for 3 months in the booster phase30 minutesNot specifiedNot reportedPark & Yim \[[@bib44]\]VR kayak programSemi-immersive2 times a week for 6 weeks20 minutes per sessionNot specifiedSome dizzinessSchwenk et al. \[[@bib37]\]A sensor-based balance training programSemi-immersive2 sessions a week for 4 weeks45 minutesFun, safety, and helpfulness were reported.No training-related adverse events occurred.Threapleton et al. \[[@bib32]\]Virtual homeNonimmersiveSingle session24 minutes in the feasibility study, 27 minutes in the pilot studyFeedback from the therapists indicated that the intervention was acceptable to them and identified further potential improvements for the content of the application.Not reportedVallejo et al. \[[@bib45]\]3D Memory IslandImmersiveSingle sessionNot specifiedAll the participants used this device easily and did not need any previous experience, but some had more difficulties with the touchpad.Not reportedWhite & Moussavi \[[@bib40]\]VR navigation taskImmersive3 sessions a week for 7 weeks45 minutes per sessionNot specifiedNot reported[^3]

3.3. Objective level of immersion {#sec3.3}
---------------------------------

[Table 3](#tbl3){ref-type="table"} shows the objective levels of immersion based on the aforementioned criteria \[[@bib7],[@bib8]\]. Most of the studies (40.9%) met the criteria for a moderate level of immersion, followed by 27.3% of high level of immersion, and 13.6 of low immersive experience. Surprisingly, the information about the immersive criteria allowing rating of the degree of immersion of the VR technology was not available in 18.2% of the studies.Table 3Immersion levels of VR technologiesAuthorInclusivenessExtensivenessSurroundingVividnessMatchingTotal scoreNumerical scoreBlackman et al. \[[@bib46]\]LowModerateModerateModerateLowModerate1.6Davis et al. \[[@bib38]\]LowLowLowLowLowLow1De Luca et al. \[[@bib27]\]ModerateHighModerateHighHighHigh2.6De Luca et al. \[[@bib28]\]ModerateHighModerateHighHighHigh2.6Delbroek et al. \[[@bib33]\]LowModerateLowInfo unavailableModerateInfo unavailable-Faria, et al. \[[@bib29]\]LowLowLowLowLowLow1Flynn et al. \[[@bib47]\]LowModerateHighHighLowModerate2Hwang & Lee \[[@bib34]\]Info unavailableInfo unavailableInfo unavailableInfo unavailableInfo unavailableInfo unavailableKim et al. \[[@bib30]\]LowModerateLowModerateModerateModerate1.6Kizony et al. \[[@bib41]\]LowModerateLowModerateModerateModerate1.6Lee et al. \[[@bib31]\]LowModerateLowModerateHighModerate1.8Man et al. \[[@bib42]\]LowLowLowLowLowLow1Manera et al. \[[@bib48]\]ModerateModerateModerateModerateLowModerate1.8Mirza & Yaqoob \[[@bib35]\]LowModerateInfo unavailableModerateHighInfo unavailable-Moyle et al. \[[@bib39]\]LowHighLowHighModerateModerate2Mrakic-Sposta et al. \[[@bib36]\]LowHighModerateModerateModerateModerate2Optale et al. \[[@bib43]\]LowModerateLowLowModerateLow1.4Park & Yim \[[@bib44]\]ModerateModerateModerateInfo UnavailableModerateInfo Unavailable-Schwenk et al. \[[@bib37]\]LowModerateLowLowModerateLow1.4Threapleton et al. \[[@bib32]\]LowLowLowModerateLowLow1.2Vallejo et al. \[[@bib45]\]LowModerateLowModerateHighModerate1.8White & Moussavi \[[@bib40]\]HighModerateHighLowHighHigh2.4

3.4. Risk of bias and quality assessment {#sec3.4}
----------------------------------------

A total quality score was calculated by rating the individual items in each of the five domains. The tool does not provide a cutoff score to classify the studies into either a low- or high-quality study, avoiding the artificial classification. The average quality score for the studies was 17.7 (SD = 4.1, range = 10--27), out of 31 possible points. We included case studies as part of this review. [Table 4](#tbl4){ref-type="table"} presents the percentage of the studies that met the criteria in the checklist.Table 4Percentages of studies meeting the criteria for quality assessmentItemQuestionPercent1Is the hypothesis/aim/objective of the study clearly described?97.72Are the main outcomes to be measured clearly described in the Introduction or Methods section?90.13Are the characteristics of the participants included in the study clearly described?95.54Are the interventions of interest clearly described?95.45[∗](#tbl4fnlowast){ref-type="table-fn"}Are the distributions of principal confounders in each group of subjects to be compared clearly described?0 = 0\
1 = 45.45\
2 = 54.56Are the main findings of the study clearly described?97.77Does the study provide estimates of the random variability in the data for the main outcomes?72,7358Have all important adverse events that may be a consequence of the intervention been reported?6.79Have the characteristics of patients lost to follow-up been described?77.310Have actual probability values been reported for the main outcomes except where the probability value is less than 0.001?7511Were the subjects asked to participate in the study representative of the entire population from which they were recruited?47.712Were those subjects who were prepared to participate representative of the entire population from which they were recruited?45.513Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive?38.614Was an attempt made to blind study subjects to the intervention they have received?015Was an attempt made to blind those measuring the main outcomes of the intervention?20.516If any of the results of the study were based on "data dredging" was this made clear?88.617In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and outcome the same for cases and controls?77.318Were the statistical tests used to assess the main outcomes appropriate?88.619Was compliance with the intervention/s reliable?72.720Were the main outcome measures used accurate (valid and reliable)?93.121Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population?70.422Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time?61.423Were study subjects randomized to intervention groups?49.924Was the randomized intervention assignment concealed from both patients and health care staff until recruitment was complete and irrevocable?6.825Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?2526Were losses of patients to follow-up taken into account?79.527[†](#tbl4fndagger){ref-type="table-fn"}Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5%?0 = 50\
3 = 18.18\
5 = 31.82[^4][^5][^6]

The analysis of Reporting, which assessed whether the information provided in the article was sufficient to allow a reader to make an unbiased assessment of the findings of the study, revealed that the distributions of principal confounders in each group of participants to be compared were not clearly described and that all important adverse events that may be a consequence of the intervention have not been reported. On average, reporting scores were high (7.8 of 10, SD = 1.6, range = 5--10).

External validity, addressing the extent to which the findings from the studies could be generalized to the population from which the study participants were derived, indicates that the staff, places, and facilities where the participants were treated were not representative of the treatment the majority of clients receive. In almost 40%, the interventions were delivered in a university laboratory, which makes sense given that these are new treatments and that some of them correspond to feasibility studies. On average, external validity scores were high (1.3 of 3, SD = 1.1, range = 0--3).

The analysis of Bias, which addressed biases in the measurement of the intervention and the outcome, revealed that there was not an attempt made to blind study participants to the intervention they have received. On average, Bias scores were high (4.4 of 7, SD = 1, range = 2--6).

Confounding, that addressed bias in the selection of study participants revealed that there was not adequate adjustment for confounding in the analyses from which the main findings were drawn. However, average confounding scores were moderate (2.9 of 6, SD = 1.4, range = 0--5).

Finally, the item evaluating Power, or whether the negative findings from a study could be due to chance indicated that only 31.8% of the studies had sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5%. In addition, average Power scores were low (1.2 of 5, SD = 1.9, range = 0--5).

Based on the criteria to classify Downs and Black score ranges \[[@bib26]\], none of the studies reached excellent quality levels (≥26). A total of 10 studies reached good quality levels (20--25) \[[@bib27],[@bib29],[@bib30],[@bib32], [@bib33], [@bib34],[@bib38],[@bib39],[@bib41],[@bib47]\], seven reached fair quality levels (15--19) \[[@bib31],[@bib36],[@bib37],[@bib42], [@bib43], [@bib44],[@bib48]\], and only five reached poor quality levels (≤14) \[[@bib28],[@bib35],[@bib40],[@bib45],[@bib46]\].

4. Discussion {#sec4}
=============

The present systematic review was conducted to study the effects of virtual reality on overall cognitive and psychological rehabilitation in individuals with NCDs. We provided descriptive analyses based on the characteristics of the studies, study samples, diagnoses, types of VR technologies, subjective and objective levels of immersion, and the risk of bias and quality assessment of 22 studies with an aggregated sample of 564 individuals with NCD. We extracted the information with two independent reviewers to increase the accuracy in the process.

The main finding is that the results of the VR interventions in individuals with NCDs indicate an improvement at different levels of cognition (e.g. memory, dual tasking, and visual attention) and an improvement in psychological functioning (e.g. reduction of anxiety, higher levels of well-being, and increased use of coping strategies). VR interventions have been mainly used in individuals with NCDs due to stroke, followed by individuals with mild cognitive impairment and AD. The evidence provided in this systematic review supports the use of VR interventions as a way to provide cognitive rehabilitation and to treat psychological symptoms in individuals with NCDs of different etiologies.

Most of the VR technologies reported subjective levels of immersion described as semi-immersive. The average number of sessions was close to 14, with a duration of approximately 30 minutes each, two or three times per week. As such, VR interventions were primarily delivered in university laboratories or hospital facilities as part of innovation initiatives. Although almost 40% of the studies did not report acceptability, VR interventions seem to be greatly accepted by individuals with NCDs (e.g. enjoyment with the technology, user satisfaction, interest, engagement, motivation, safety, helpfulness, and easiness of use). Adverse effects do not seem to be exclusive of NCDs (e.g. simulator sickness, negative emotions when participants fail in specific activities facilitated by the technology, oculomotor disturbances, nausea, disorientation, neck pain, and some dizziness), as they have been reported in only 5% of participants in a study of VR aiming to document those effects \[[@bib51]\]. As such, adverse effects need to be monitored but do not represent a reason for exclusion on their own.

Most of the studies met objective criteria for moderate levels of immersion. Higher levels of immersion can increase the user experience and play a major role in the sense of presence. The sense of presence corresponds to the experience of actually feeling "being there," as in a real-world situation, which is vital to substantially affect the behavioral responses \[[@bib17]\]. In the present state of the literature, we do not know if a fully immersive VR technology is better than a moderate or low immersive VR technology in individuals with NCDs.

Although the overall quality of the studies was good, it is important to insist on the documentation of adverse effects, make sure to attempt to blind study participants to the intervention they receive, and make sure to adjust for confounding in the analyses from which the main findings are drawn and increase power. In regard to the external validity, the results of this systematic review indicate that the staff, places, and facilities where the participants were treated were not representative of the treatment the majority of clients receive. This was expected as VR technologies are being developed, and their use is in the early stages. There were no studies that could achieve a quality level of excellent in accordance with the scoring methodology of the Downs and Black checklist. As such, future research needs to focus on randomized controlled studies.

5. Conclusion and recommendations for research and practice {#sec5}
===========================================================

In conclusion, we presented a systematic review of the literature on VR technologies for the rehabilitation of cognition and psychological functioning in minor and major NCDs. VR interventions are useful to improve cognition (e.g. memory, dual tasking, and visual attention) and psychological functioning (e.g. reduction of anxiety, higher levels of well-being, and increased use of coping strategies) in individuals with NCD. VR interventions are mainly used in individuals with NCDs due to stroke. Although this systematic review was not suitable for a meta-analysis, the results indicate that VR interventions are helpful and promising in providing cognitive rehabilitation and to treat psychological symptoms in individuals with NCDs of different etiologies, which should be further explored in future with well-designed studies.

Based on the conclusions of the present review, the following recommendations for future studies can help to increase research in individuals with NCDs.1.To describe the clinical information of the samples. The type and severity of NCD are very important to be able to compare findings across studies. The use of widely known instruments to track cognitive changes (e.g. MMSE and MoCA) and a clear diagnosis allow clinicians to easily identify candidates for these interventions.2.To conduct longitudinal studies on VR interventions of NCDs. Longitudinal studies allow capturing the progression of NCDs and help to observe whether the benefits of the VR interventions are maintained with the evolution of the disease.3.To compare different levels of immersion. To date, we do not know whether higher levels of immersion are more effective to treat cognitive and psychological problems in individuals with NCDs, as compared to lower levels of immersion.4.To systematically assess user acceptance and adverse effects. We do not know whether adverse effects or acceptance levels differ in NCDs of different etiologies or in the same NCD at different stages of the disease.5.To use widely known measures for cognition and psychological outcomes showing cross-cultural validity. The use of core instruments that have been developed and used in different cultures will allow performing a meta-analysis and facilitate comparisons across studies.6.Report effect sizes for all the outcomes. This will allow readers to have a better appreciation of the effect of VR interventions on cognition.7.Provide examples of generalization to real-life situations. This could provide evidence that the results of VR interventions have an impact on the everyday life of individuals with NCDs. Measures can be collected through family caregiver reports or professional caregivers.Research in context1.Systematic review: The authors conducted a systematic review of the published literature on immersive and nonimmersive virtual reality technologies targeting cognition in minor and major neurocognitive disorders following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.2.Interpretation: Virtual reality interventions are useful to improve cognition (e.g. memory, dual tasking, and visual attention) and psychological functioning (e.g. reduction of anxiety, higher levels of well-being, increased use of coping strategies) in individuals with minor and major neurocognitive disorders.3.Future directions: To improve research in this area, we recommend to describe the clinical information of the samples, to conduct longitudinal studies on virtual reality interventions of neurocognitive disorders, to compare different levels of immersion, to systematically assess user acceptance and adverse effects, to use widely known measures for cognition and psychological outcomes showing cross-cultural validity, to report effect sizes for all the outcomes, and to provide examples of generalization to real-life situations.
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[^1]: Abbreviations: VR, virtual reality; AD, Alzheimer\'s disease; MMSE, Mini-Mental State Examination; MCI, mild cognitive impairment; MoCA, Montreal Cognitive Assessment; WAIS, The Wechsler Adult Intelligence Scale; WCT, Word Color Test; ABI, acquired brain injury; MS, multiple sclerosis; CDR, Clinical Dementia Rating Scale; TMT, Trail Making Test; RAVLT, Rey Auditory Verbal Leaning Test; ROCFT, Rey-Osterrieth Complex Figure Test; NIHSS, National Institute of Health Stroke Scale.

[^2]: The effect size was not reported, but it was calculated based on data available.

[^3]: Abbreviations: VR, virtual reality; VE, virtual environment; MCI, mild cognitive impairment.

[^4]: NOTE. (A) study quality -- 10 items (items 1--10), (B) external validity -- 3 items (items 11--13), (C) study bias -- 7 items (items 14--20), (D) confounding and selection bias -- 6 items (items 21--26), (E) power of the study -- 1 item (item 27).

[^5]: 0 = No; 1 = Partially, 2 = Yes.

[^6]: 0 = No power calculation is provided; 3 = The power calculation is provided, but the importance or impact of the difference between groups used in the calculation is unclear; 5 = The difference between groups is clearly defined as a clinically important difference.
